Clinical trial NCT03321825: Evaluation of the Merz Cheek Fullness Assessment Scale in the Treatment of Midface Volume Deficit
Official title: Evaluation of the Merz Cheek Fullness Assessment Scale in the Treatment of Midface Volume Deficit
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Moderate to Severe Midface Volume Deficit
Lead sponsor: Merz North America, Inc.
Sponsor class: INDUSTRY
First posted: 2017-10-26
Enrollment: 66
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Evaluation of the sensitivity of the Merz Cheeks Fullness Assessment Scale (MCFAS) and the clinical relevance of aesthetically pleasing outcomes by detecting changes in cheek appearance after Belotero® Volume Lidocaine injection.

The safety objectives include the identification and description of adverse events (AEs), adverse device effects (ADEs), serious adverse events (SAEs), serious adverse device effects (SADEs), anticipated serious adverse device effects (ASADEs) and unanticipated adverse device effects (UADEs) during the course of the study. Additionally, common treatment site responses (CTRs) will be assessed.


Eligibility criteria: Inclusion Criteria:

* 1. Has right and left cheek volume deficit with a rating of 2 or 3 (moderately or severely sunken cheeks) on the MCFAS as determined by the blinded evaluator.
* 2. Has the same MCFAS score on both cheeks (i.e., cheeks are symmetrical).
* 3. Is at least 18 years of age.
* 4. Understands and accepts the obligation not to receive any other procedures (i.e., dermal fillers, toxin treatments, facial ablative or fractional laser, microderm abrasion, chemical peels, non-invasive skin-tightening \[e.g., Ultherapy, Thermage\] and/or surgical procedures) in the face during participation in the study.

Exclusion Criteria:

* 1. Skin atrophy in the midfacial region other than that related to age.
* 2. Has gained or lost and ≥ 2 body mass index (BMI) units within the previous 90 days or has the intention to gain or lose a significant amount of weight during the course of the study.
* 3. Unphysiological skin laxity and/or sun damage beyond typical for the subject's age or subject plans to tan during the study period.
* 4. Acute inflammatory process or infection at the injection site (e.g., acne, eczema, streptococcus infections), or history of chronic or recurrent infection or inflammation with the potential to interfere with the study results or increase the risk of AEs.
* 5. Prior surgery, including midfacial plastic surgery, or has a permanent implant or graft in the midfacial region that could interfere with effectiveness assessments.
* 6. Undergone oral surgery in the past 30 days or plans to undergo oral surgery during participation in the study (i.e., orthodontia, extraction, implants).
* 7. Ever been treated with fat injections or permanent and/or semi-permanent dermal fillers in the midfacial region or plans to receive such treatments during participation in the study.
* 8. Received midfacial region treatments with porcine-based collagen fillers or with Belotero Volume, JUVÉDERM VOLUMA®, or Restylane® Lyft, calcium hydroxylapatite (CaHA), poly L-lactic acid (PLLA), or mesotherapy within the past 24 months and/or with other hyaluronic acid (HA) products within the past 12 months or plans to receive such treatments during participation in the study.
* 9. Received facial dermal therapies (i.e., toxin treatments, facial ablative or fractional laser, microderm abrasion, chemical peels, non-invasive skin-tightening \[e.g., Ultherapy, Thermage\] and surgical procedures) in the midface region within the past 12 months or plans to receive them during participation in the study.
* 10. Facial nerve palsy or history of facial nerve palsy.
* 11. A history or documented evidence of an autoimmune disease (e.g., scleroderma, lupus erythematosus, rheumatoid arthritis).
* 12. A known bleeding disorder or has received or is planning to receive anti-coagulation, anti-platelet, or thrombolytic medications (e.g., warfarin), anti-inflammatory drugs (e.g., aspirin, ibuprofen), or other substances known to increase coagulation time (vitamins or herbal supplements, e.g., vitamin E, garlic, gingko), from 10 days before to 3 days after injection.

Primary outcomes:
measure: Comparison of the responder rate between the treatment group and the untreated control group at Week 4, according to the Merz Cheeks Fullness Assessment Scale (MCFAS) as assessed by a blinded evaluator.
timeFrame: Week 4
Secondary outcomes:
measure: Descriptive summary of the FACE-Q satisfaction of the midface for treated subjects at baseline and Week 4
timeFrame: Week 4
measure: Average percent change of the FACE-Q satisfaction of the midface for treated subjects from baseline to Week 4
timeFrame: Week 4
measure: Descriptive summary of Global Aesthetic Improvement Scale (GAIS) scores for treated subjects at Week 4, as completed by the treating investigator.
timeFrame: Week 4
measure: Descriptive summary of GAIS scores for treated subjects at Week 4, as completed by the subject.
timeFrame: Week 4
measure: Evaluate the incidence and nature of device- and/or injection-related AEs, and SAEs observed during the study.
timeFrame: Week 4
measure: Common treatment site responses (CTRs) will be evaluated using subject diaries
timeFrame: Week 4
Other outcomes:
Locations:
city: Oakville
country: Canada
facility: Institute of Cosmetic and Laser Surgery; Merz Inverstigational Site #0010409
state: Ontario
city: Toronto
country: Canada
facility: Research Toronto; Merz Investigational Site #0010408
state: Ontario
city: Toronto
country: Canada
facility: Cosmetic Dermatology Toronto Yorkville; Merz Investigational Site #'0010412
state: Ontario
Study officials:
affiliation: Merz Pharmaceuticals GmbH
name: Merz Scientific Expert
role: STUDY_DIRECTOR
References: